Precisionlife
- Company typePrivate
- Founded2015
- HeadquartersWitney, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Precisionlife firmographics
Firmographics- Name
- Precisionlife
- Legal name
- PrecisionLife Ltd
- Website
- https://precisionlife.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Precisionlife industry classification
Industry- Product category
- Precision Medicine AI Software
- NAICS
- Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA)
- akta.pro secondary industries
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)
Keywords
Where Precisionlife is headquartered
LocationHeadquarters
- HQ city
- Witney
- HQ country
- United Kingdom
- HQ region
- Europe
Offices5 records
Markets served
Precisionlife business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Tests (Mechanostics®): Revenue from development and commercialization of genetic diagnostic tests including GLP-1 response tests, disease risk prediction tests, and patient stratification tools for healthcare providers and payors.
- Biopharmaceutical Partnerships: Revenue from partnerships with pharmaceutical companies for drug discovery, clinical trial enrichment, patient stratification biomarkers, and drug repurposing opportunities. Includes biomarker discovery services and companion diagnostic development.
- Payor-Facing Tests: Mechanism-based tests to help payors and healthcare systems determine where therapies are most clinically and economically justified, supporting value-based reimbursement frameworks.
- Laboratory Developed Tests (LDTs): Revenue from laboratory developed tests commercialized through CLIA-certified laboratory partners, including consumer DNA tests and clinical diagnostic tests.
Go-to-market motion1 record
Distribution channels5 records
Marketing channels8 records
Precisionlife product offering
Product offeringCore offering
PrecisionLife develops a proprietary AI-driven combinatorial analytics platform that identifies the biological mechanisms driving complex chronic diseases and enables high-resolution patient stratification. The company commercializes the Mechanostics® product line of non-invasive genetic tests for disease risk prediction, treatment response prediction, and patient stratification, and provides biomarker discovery, drug target identification, and clinical trial enrichment services to biopharmaceutical companies, healthcare systems, and payors.
Product overview
PrecisionLife offers a unified precision medicine platform centered on its Mechanostics® product line and proprietary Combinatorial Analytics Platform. The core offering includes non-invasive genetic tests that identify disease mechanisms and predict treatment response across 60+ chronic diseases. Key products include GLP-1 response prediction tests (LDT and consumer DNA), endometriosis tests (TRANSCEND), ME/CFS genetic tests, and long COVID diagnostic tests. The company provides additional services including Clinical Decision Support, Drug Discovery, and Clinical Trial Enrichment using mechanism-based patient stratification. All products leverage the Combinatorial Analytics Platform to discover biomarkers invisible to traditional GWAS methods.
Differentiator
Problem solved
Functional benefit
Brands
- Mechanostics®: A new generation of diagnostic and prognostic tools to accurately identify the cause of disease and personalize interventions, based on precision medicine AI technology.
Products and services
- Mechanostics® First-in-class, non-invasive genetic tests that leverage PrecisionLife's proprietary AI-driven combinatorial analytics to identify the underlying biological mechanisms driving disease in patients. Enables disease risk prediction, mechanism identification, and precision treatment matching across 60+ chronic diseases.
- Combinatorial Analytics Platform Proprietary AI platform that identifies combinations of genetic variants associated with disease risk and treatment response. Generates 10-100x more signal from data than traditional GWAS approaches, discovering disease mechanisms invisible to other analytical methods.
- GLP-1 Response Prediction Tests DNA-based tests (both LDT and direct-to-consumer) that predict individual patient response, safety, and tolerability to GLP-1 receptor agonists. Identifies biomarkers for glycemic control (HbA1c) and weight loss (BMI) responses using over 2,500 genetic signatures mapped to 1,100 genes.
- Endometriosis Test (TRANSCEND) Non-invasive buccal swab test to evaluate patient risk of endometriosis and the biological mechanisms underpinning their disease. Enables rapid differential triage and identification of effective treatments for patients presenting with pelvic pain.
- ME/CFS Genetic Test Genetic biomarker tests identifying over 250 core genes associated with myalgic encephalomyelitis, revealing disease subgroups and drug repurposing opportunities. Validated across DecodeME and UK Biobank cohorts.
- Long COVID Diagnostic Test Biomarker-driven test to evaluate individual genetic risk of developing long COVID and distinguish it from other post-viral syndromes. Based on reproducible genetic associations confirmed across US and UK diverse populations.
- Clinical Decision Support Healthcare solution enabling clinicians to make evidence-based treatment decisions using mechanism-based patient stratification and biomarker insights.
- Clinical Trial Enrichment Service Drug development service using patient stratification biomarkers to identify super-responder subgroups, design faster and smaller trials, and provide companion diagnostic biomarkers for regulatory approval.
- Drug Discovery Service Novel drug target discovery and drug repurposing identification using combinatorial analytics to find mechanistic links between disease biology and therapeutic opportunities.
- DiseaseBank Comprehensive database of disease mechanisms and genetic insights supporting research and clinical decision-making across 60+ chronic diseases.
Quantifiable outcome
- Identified over 2,500 genetic signatures for GLP-1 efficacy in 100% of 4,600 patients studied
- +4 more outcomes
Companies that use Precisionlife
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles4 records
Precisionlife technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
Precisionlife partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- Ovation.iocoreStrategic collaboration to develop GLP-1 pharmacogenomics tests for payors and healthcare systems. Phase 1 analyzed 4,600 patients identifying 2,500+ genetic signatures; Phase 2 expanding to 25,000 patients. Commercialization agreement signed April 2026 for LDT and consumer DNA tests launching H2 2026.
- Complex Disorders AlliancecoreResearch partnership for long COVID and ME/CFS studies. Successfully reproduced 88% of long COVID genetic associations across US and UK populations. Funded MELO clinical study with Metrodora Institute.
- Owkincore2025 co-development agreement for immuno-oncology candidates using AI-driven analytics platforms from both companies.
- Metrodora InstitutecoreClinical research collaboration for MetX and MELO studies evaluating biomarkers in ME/CFS and long COVID. Partnership for decentralized patient engagement, specimen collection, and genotyping to advance diagnostic tests and drug repurposing candidates.
- Action for MEcoreLOCOME project partnership leveraging DecodeME study data to categorize ME and Long COVID patients into distinct subgroups. £600,000+ Innovate UK funding. Collaboration to identify disease signatures and stratification tools for clinical trials.
- University of EdinburghcoreAcademic research partnership with DecodeME team led by Prof Chris Ponting for ME/CFS genetic studies. LOCOME project collaboration analyzing DecodeME and UK Biobank datasets to identify disease mechanisms and patient subgroups.
- Absci Corpcore2023 R&D partnership using PrecisionLife's combinatorial analytics platform for biomarker discovery and drug development. Strategic collaboration for identifying drug targets and patient stratification biomarkers.
Scale indicators19 records
Recent moves8 records
Expansion highlights8 records
Precisionlife competitors and assessment
Company assessmentDirect peers
- Sophia Genetics: AI-driven genomics and multimodal data analytics platform serving hospitals, labs, and biopharma for clinical genomics and patient stratification. Comparable to PrecisionLife's combinatorial analytics approach in chronic disease and biopharma R&D support.
- Owkin: AI precision medicine company with biopharma co-development model (including the existing PrecisionLife partnership). Uses multimodal patient data to identify targets, biomarkers, and patient subgroups for drug development, particularly in oncology.
- Congenica: Clinical genomics and rare disease diagnostics platform leveraging AI for variant interpretation and patient stratification. Comparable as a UK-based precision medicine company providing clinical decision support and biopharma genomics services.
- Verge Genomics: AI-driven drug discovery company using multi-omic patient data to identify novel targets and patient subgroups for complex diseases including neurodegenerative conditions. Comparable in AI + multi-omics approach to mechanism-based drug discovery.
- Genomics PLC: UK-based genomic analytics company using polygenic risk scores and population genomics for disease risk prediction and biopharma research. Comparable in UK origin, chronic disease focus, and B2B model serving payors and pharma.
Broad incumbents
- Tempus Labs: Large precision medicine company applying AI to multi-modal patient data including genomics, transcriptomics, and clinical records to support diagnostics, therapy selection, and biopharma drug development. Comparable in data modality breadth and biopharma service model.
- Human Longevity Inc: Precision health company combining whole genome sequencing, advanced imaging, and AI-driven analytics for disease risk prediction and preventive care. Comparable in whole-genome-driven mechanism-based risk prediction.
Emerging players
- BC Platforms: Genomic data management and analytics platform enabling precision medicine and biopharma R&D across European and global markets. Comparable in B2B genomics infrastructure and partnership-based commercialization.
- Fabric Genomics: AI-driven clinical genomic interpretation platform for rare disease and hereditary conditions, serving clinical labs and hospitals. Comparable in applying AI to clinical genomic decision-making but more focused on rare disease than chronic complex disease.
- Arcturis Data: Real-world multi-omic and clinical data platform partnered with the NHS to support biopharma drug development and precision medicine research. Comparable in multi-omic + clinical data integration for biopharma partnerships.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights1 record
Customer concentration
Precisionlife social profiles
Digital presencePrecisionlife compliance and trust
Trust signalCompliance2 records
Precisionlife financial estimates
Financial estimateRevenue estimate
Valuation estimate
Precisionlife leadership team
Management profileNumber of profiles
Profiles12 records
Precisionlife funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Precisionlife M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Precisionlife
What does Precisionlife do?
PrecisionLife develops a proprietary AI-driven combinatorial analytics platform that identifies the biological mechanisms driving complex chronic diseases and enables high-resolution patient stratification. The company commercializes the Mechanostics® product line of non-invasive genetic tests for disease risk prediction, treatment response prediction, and patient stratification, and provides biomarker discovery, drug target identification, and clinical trial enrichment services to biopharmaceutical companies, healthcare systems, and payors.
Is Precisionlife a public or private company?
Precisionlife is a private company. It is classified as venture growth investor backed and is currently operating.
When was Precisionlife founded?
Precisionlife was founded in 2015. It employs 11 to 50 people.
Where is Precisionlife based?
Precisionlife is headquartered in Witney, United Kingdom, in the Europe region.
How does Precisionlife make money?
Four revenue lines are on record. Diagnostic Tests (Mechanostics®) is the primary driver. The others are biopharmaceutical Partnerships, payor-Facing Tests and laboratory Developed Tests (LDTs).
Who are Precisionlife's main competitors?
Direct peers on record are Sophia Genetics, Owkin, Congenica, Verge Genomics and Genomics PLC. Broad incumbents are Tempus Labs and Human Longevity Inc. Emerging players are BC Platforms, Fabric Genomics and Arcturis Data.
Does Precisionlife have an API?
No public API is recorded for Precisionlife.
What industry is Precisionlife in?
Precisionlife's product category is Precision Medicine AI Software. Its primary akta.pro industry code is HLAAANAA, Genomic Profiling & Sequencing-Based Precision Medicine, with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 6215 and its SIC code is 2835.